Princeton Alpha Management’s Celldex Therapeutics CLDX Stock Holding History

Princeton Alpha Management’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-734	Closed	-$48K	–	773
2016 Q2	$48K	Buy	+734	New	+$46.6K	0.01%	745
2016 Q1	–	Sell	-1,401	Closed	-$330K	–	751
2015 Q4	$330K	Buy	+1,401	New	+$305K	0.06%	466
2015 Q2	–	Sell	-586	Closed	-$245K	–	724
2015 Q1	$245K	Sell	586 -955	-62%	-$342K	0.05%	537
2014 Q4	$422K	Buy	1,541 +501	+48%	+$125K	0.12%	277
2014 Q3	$202K	Buy	+1,040	New	+$227K	0.05%	562

Other funds holding CLDX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

CWAM

Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Princeton Alpha Management's CLDX Position: Q3 2016 in Review

Princeton Alpha Management sold out of Celldex Therapeutics (CLDX) in Q3 2016, closing a stake of 734 shares — an estimated $48K sold.

Princeton Alpha Management first reported a position in CLDX in Q3 2014 and held it in 5 quarters. The position peaked at $422K in Q4 2014. 139 funds tracked by Wall St. Rank hold CLDX as of Q3 2016.

Princeton Alpha Management reported no remaining Celldex Therapeutics position as of Q3 2016 after selling out during the quarter.
Princeton Alpha Management sold 734 Celldex Therapeutics shares in Q3 2016, an estimated $48K.
Princeton Alpha Management first reported a position in Celldex Therapeutics in Q3 2014 and held it in 5 quarters.
Princeton Alpha Management's Celldex Therapeutics position peaked at $422K in Q4 2014.
139 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2016.

Based on Princeton Alpha Management's 13F filing for Q3 2016, filed 10 Nov 2016.